[go: up one dir, main page]

MA30982B1 - Combinaison - Google Patents

Combinaison

Info

Publication number
MA30982B1
MA30982B1 MA31973A MA31973A MA30982B1 MA 30982 B1 MA30982 B1 MA 30982B1 MA 31973 A MA31973 A MA 31973A MA 31973 A MA31973 A MA 31973A MA 30982 B1 MA30982 B1 MA 30982B1
Authority
MA
Morocco
Prior art keywords
combination
aml
relates
mds
hdai
Prior art date
Application number
MA31973A
Other languages
English (en)
Inventor
Peter Wisdom Atadja
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39272127&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA30982(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA30982B1 publication Critical patent/MA30982B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'INVENTION CONCERNE UNE COMBINAISON QUI COMPREND : (A) UN HDAI; ET (B) UN ANTIMÉTABOLITE, POUR UN USAGE SIMULTANÉ, CONCURRENT, SÉPARÉ OU SÉQUENTIEL, EN PARTICULIER POUR UN USAGE DANS LE TRAITEMENT DE MALADIES PROLIFÉRATIVES, PLUS PARTICULIÈREMENT LE MDS (SYNDROME MYÉLODYSPLASIQUE) OU L'AML (LEUCÉMIE MYÉLOÏDE AIGUË). L'INVENTION CONCERNE AINSI DES COMPOSITIONS PHARMACEUTIQUES, COMPRENANT UNE TELLE COMBINAISON, ET UN PROCÉDÉ DE TRAITEMENT DU MDS ET DE L'AML CHEZ LES MAMMIFÈRES, EN PARTICULIER CHEZ L'HOMME, AVEC UNE TELLE COMBINAISON. LA PRÉSENTE INVENTION CONCERNE EN OUTRE UN CONDITIONNEMENT COMMERCIAL OU UN PRODUIT COMPRENANT UNE TELLE COMBINAISON.
MA31973A 2006-12-04 2009-06-10 Combinaison MA30982B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86838806P 2006-12-04 2006-12-04

Publications (1)

Publication Number Publication Date
MA30982B1 true MA30982B1 (fr) 2009-12-01

Family

ID=39272127

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31973A MA30982B1 (fr) 2006-12-04 2009-06-10 Combinaison

Country Status (25)

Country Link
US (1) US8093220B2 (fr)
EP (1) EP2099451B1 (fr)
JP (3) JP5784274B2 (fr)
KR (1) KR101475538B1 (fr)
CN (1) CN101553223A (fr)
AR (1) AR064072A1 (fr)
AU (1) AU2007328281B2 (fr)
BR (1) BRPI0719746A2 (fr)
CA (1) CA2670741C (fr)
CL (1) CL2007003467A1 (fr)
EC (1) ECSP099483A (fr)
ES (1) ES2569477T3 (fr)
GT (1) GT200900148A (fr)
IL (1) IL198638A (fr)
MA (1) MA30982B1 (fr)
MX (1) MX2009005946A (fr)
MY (1) MY148893A (fr)
NO (1) NO20092473L (fr)
PE (1) PE20081303A1 (fr)
PL (1) PL2099451T3 (fr)
RU (1) RU2469717C2 (fr)
TN (1) TN2009000213A1 (fr)
TW (1) TW200831075A (fr)
WO (1) WO2008070011A2 (fr)
ZA (1) ZA200903041B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2519474T3 (es) 2008-03-26 2014-11-07 Novartis Ag Inhibidores de las desacetilasas B basados en hidroxamato
BRPI0915927A2 (pt) * 2008-07-18 2016-06-07 Novartis Ag uso de inibiodores de hdac para o tratamento da doença de hodgkin
WO2010009285A1 (fr) * 2008-07-18 2010-01-21 Novartis Ag Utilisation d'inhibiteurs de hdac pour le traitement d'une leucémie myéloïde aiguë et/ou d'un syndrome myélodysplasique
US20110053925A1 (en) * 2009-08-28 2011-03-03 Novartis Ag Hydroxamate-Based Inhibitors of Deacetylases
JP6031437B2 (ja) * 2010-06-07 2016-11-24 アブラクシス バイオサイエンス， エルエルシー 増殖性疾患を処置するための組み合わせ療法
CA2808908A1 (fr) * 2010-09-01 2012-03-08 Novartis Ag Association d'inhibiteurs de hdac et de medicaments contre la thrombopenie
CA2903473A1 (fr) * 2013-03-12 2014-10-09 Quanticel Pharmaceuticals, Inc. Inhibiteurs d'histone demethylase
JP2016538310A (ja) * 2013-11-27 2016-12-08 オンコエシックス ゲーエムベーハー チエノトリアゾロジアゼピン化合物を含む医薬製剤を用いる白血病の治療方法
AU2015318111A1 (en) 2014-09-17 2017-04-13 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
EP3932914A1 (fr) 2015-03-13 2022-01-05 Valo Health, Inc. Composés alpha-cinnamidiques et compositions comme inhibiteurs de hdac8
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US6905669B2 (en) * 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
CA2526908A1 (fr) * 2003-05-21 2004-12-02 Novartis Ag Combinaison d'inhibiteurs d'histone deacetylase avec des agents chimiotherapeutiques

Also Published As

Publication number Publication date
AU2007328281B2 (en) 2011-03-31
JP2010511702A (ja) 2010-04-15
KR20090087115A (ko) 2009-08-14
CA2670741C (fr) 2016-04-12
HK1132462A1 (zh) 2010-02-26
ES2569477T3 (es) 2016-05-11
JP5784274B2 (ja) 2015-09-24
WO2008070011A3 (fr) 2008-07-24
US8093220B2 (en) 2012-01-10
IL198638A0 (en) 2010-02-17
CA2670741A1 (fr) 2008-06-12
JP2016006070A (ja) 2016-01-14
MY148893A (en) 2013-06-14
NO20092473L (no) 2009-09-01
TW200831075A (en) 2008-08-01
EP2099451B1 (fr) 2016-02-10
MX2009005946A (es) 2009-06-17
GT200900148A (es) 2011-08-02
KR101475538B1 (ko) 2014-12-22
RU2469717C2 (ru) 2012-12-20
RU2009125439A (ru) 2011-01-20
EP2099451A2 (fr) 2009-09-16
CN101553223A (zh) 2009-10-07
ZA200903041B (en) 2010-03-31
US20100069318A1 (en) 2010-03-18
ECSP099483A (es) 2009-08-28
WO2008070011A2 (fr) 2008-06-12
PE20081303A1 (es) 2008-10-28
CL2007003467A1 (es) 2008-07-11
AR064072A1 (es) 2009-03-11
TN2009000213A1 (en) 2010-10-18
BRPI0719746A2 (pt) 2013-12-10
AU2007328281A1 (en) 2008-06-12
PL2099451T3 (pl) 2016-07-29
IL198638A (en) 2015-06-30
JP2014097992A (ja) 2014-05-29

Similar Documents

Publication Publication Date Title
MA30982B1 (fr) Combinaison
LUC00011I2 (fr)
MA31605B1 (fr) Anticorps anti-cd79b humanisés, immunoconjugués, et procédés d'utilisation
EP2214480A4 (fr) Procédés de traitement d'une stéatohépatite non alcoolique au moyen de produits à base de cystéamine
MA32458B1 (fr) Combinaison d'un antagoniste de c-met et d'un compose aminoheteroaryle pour le traitement d'un cancer
EA200700353A1 (ru) Средство антимикробного действия
MA32012B1 (fr) Octahydroquinolizines destinees au traitement du diabete
MA27634A1 (fr) Traitement de maladies proliferatives au moyen de derives d'epothilone et d'une exposition a des rayonnements
MA29735B1 (fr) Composition de microparticules contenant un inhibiteur de la topoisomerase 1, la 7-tert-butoxyiminomethylcamptothecine
TW200510348A (en) 5-aryltetrazole compounds, compositions thereof, and uses therefor